Industry: Biotechnology Region: Spain Deal price: $1 million Deal Method: Equity investment
The Spanish company is GLP certified, FDA inspected, GCP compliant and ANVISA certified CRO, providing a comprehensive range of high quality bioanalytical services to the global pharmaceutical, biotechnology and generics industries.
Details: The company's services include:
Small molecular bioanalysis
● With more than 30 years of experience in bioanalysis, experts specializing in LC-MS/MS technology guide you through any small molecule drug development
● New Chemical Entities (NCE)
Low Generics (up)
Biomarkers
Macromolecular bioanalysis
- - A series of ligand binding assays (LBA) and LC-MS/MS technology platforms to support biologics development programs from early preclinical to phase 1-11 clinical.
● Comprehensive LC-MS /MS, LBA bioanalysis services.
Methods development and validation, sample analysis, Generics, Biomarkers, immunity analysis, policies and regulations, etc.
Service advantages
● Professional team
Rigorously trained scientists with over 30 years LC/MS.MS experience in bioanalysis and over 15 years ligand binding assay (LBA) experience ensure that the highest level of expertise and quality is the standard for clients at any stage of drug development. Each senior employee has more than 10 years of proven experience.
● Advanced hardware and software facilities
With a state-of-the-art experimental portal, equipped with the most advanced high performance liquid chromatography mass spectrometry (LC-MS/ MS) and ligand binding analysis (LBA) technology platform, it is designed to meet all the scientific, regulatory and quality requirements required to support the pharmaceutical industry's drug development efforts.
● Quality assurance
With GLP certification, FDA certification, GCP certification, ANVISA certification, we have a strong quality system to ensure the provision of consistent, reproducible and reliable data required for international registration.